Anti-idiotype cancer vaccine (Viventia Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-idiotype cancer vaccine (Viventia Biotech)
Drug Alias Name4B5Monoclonal antibody 4B5NOVOVAC-M1
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViventia Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViventia Biotech Inc
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A